Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plutonium (Pu), Americium (Am), and Curium (Cm) ions are radioactive metal cations belonging to the actinide series. All are synthetic elements, intensely radioactive with multiple isotopes; they are primarily encountered as environmental contaminants due to nuclear fuel processing, accidents, or improper waste disposal. Their ions (most stable in oxidation state +3) readily bind to biological molecules, especially in bone and liver, posing significant health hazards, including cancer and tissue destruction. They have no natural biological function or therapeutic relevance, but are targets of chelation therapy in cases of contamination. Their grouping as a single molecular target is incorrect; each ion is a distinct chemical entity.
Chelation/complexation: Drugs bind to these ions, increasing their excretion from the body
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plutonium, Americium, and Curium ions (Pu³⁺, Am³⁺, Cm³⁺).